Assessment of the tolerability and efficacy of amlodipine in 9295 patients with mild or moderate essential hypertension

Clinical Drug Investigation

Volumn 13, Issue SUPPL. 1, 1997, Pages 137-142

  Pessina, A C ^a   Gallucci, M ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b SGiovanni Hospital Agency   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD PRESSURE REGULATION; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DATA ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; ELECTROCARDIOGRAM; ESSENTIAL HYPERTENSION; EXPERIENCE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; STOMACH PAIN; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; VERTIGO;

EID: 0030791327     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199700131-00024     Document Type: Article

References (17)

1. Lombardi M, Del Guercio M, Leonardo G, et al. Trattamento dell'ipertensione arteriosa con terazosina. Minerva Angiol 1990; 15: 467-9
2. Kannel WB. The Framingham Study. An epidemiological investigation of cardiovascular disease. 74-599. Department of Health, Education and Welfare, Washington DC, Section 30
3. Catapano A. The antiatherogenic potential of calcium antagonists: experimental evidence. J Cardiovasc Pharmacol 1992; 20 Suppl. A: S44-50
4. Vetrovec GW. Hemodynamic and electrophysiologic effects of first and second generation of calcium antagonists. Am J Cardiol 1994; 73: 34-8A
5. Nayler WG, Xin Nua Gu. Protecting the vasculature: an eye toward the future. Am J Cardiol 1990; 66: 23-7
6. Abernethy DR. Amlodipine pharmacokinetic profile of a low clearance calcium antagonist. J Cardiovasc Pharmacol 1991; 17 Suppl. 1: S4-7
7. Bompadre S, Bedetta C, Capone P, et al. Pharmacokinetics and pharmacodynamics of amlodipine in comparison with nifedipine AR in patients with mild to moderate hypertension. Curr Ther Res 1991; 49: 832-42
8. Burges RA, Dodd MG. Amlodipine. Cardiovasc Drug Rev 1990; 8: 25-44
9. Faulkner JK, McGibney D, Chasseaud LF, et al. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol 1986; 22: 21-5
10. Heber ME, Brioden G, Raftery EB. 24h blood pressure control with the once daily calcium antagonist amlodipine. Br J Clin Pharmacol 1989; 27: 359-65
11. Mroczek WJ, Burris JF, Allenby KS. Effect of amlodipine on 24 hour ambulatory blood pressure in hypertensive patients. J Cardiovasc Pharmacol 1991; 17 Suppl. 1: S13-5
12. Osterloh JH. An update on the safety of amlodipine. J Cardiovasc Pharmacol 1991; 17 Suppl. 1: S6-8
13. World Health Organization. Tech. rep. 2317: 1962
14. Fisher M, Grotta J. New uses for calcium channel blockers. Drugs 1993; 46 (6): 961-75
15. Circo A, Scaccianoce G, Platania F, et al. Amlodipine versus nifedipine R nel trattamentodellacardiopatia ischemica. Clin Ter 1992; 40: 43-57
16. Taylor SH, Lee P, Jackson N, et al. A double-blind, placebo-controlled, parallel dose-response study of amlodipine in stable exertional angina pectoris. J Cardiovasc Pharmacol 1991; 17 Suppl. 1: S46-9
17. Packer M, Nicod P, Khandheria BR, et al. Randomized, multicenter, double-blind, placebo controlled evaluation of amlodipine in patients with mild-to-moderate heart failure. JACC 1991; 17: 274A